Biological therapy cycles

Towards tailored, needs-driven, safer and cost-effective management of Crohn’s disease.'

Europe flag

This project receives funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 633168 – BIOCYCLE (PHC-13-2014).

Objective

The objective of the BIOCYCLE project is to assess long-term treatment strategies in Crohn’s disease that will improve both safety and related costs while ensuring a constant level of efficacy during maintenance therapy.

Crohn’s disease is a chronic longstanding disease that can’t be cured with current available treatments. The aim of long-term treatment is to fully control the symptoms and avoid the progression of intestinal damage. Currently, the preferred strategy for moderate-severe disease is a combination therapy with anti-TNFα and anti-metabolites (immunosuppressant). This long-term treatment may lead to cost and safety issues. The BIOCYCLE action will assess the efficacy, safety, effectiveness and feasibility of either anti-TNFα or immunosuppressant withdrawal in those patients.

Project overview

Crohn's disease

Crohn image medecin

Description of the disease

Crohn’s disease (CD) is a chronic inflammatory bowel disease (IBD) affecting the gastro-intestinal tract. CD often begins at young age and lasts the whole life. The prevalence is 20-30% higher for women than for men. CD is characterized by a sequence of active disease episodes (flare-ups) and remissions of variable duration. The chronicity of CD has a significant impact on patients’ quality of life (QoL).

Crohn image

Treatment

Curative therapies do not yet exist and the current best treatments are symptoms relieving therapies. The drug of choice and treatment strategies depend on the clinical characteristics and severity of the disease.

Partners

The BIOCYCLE project involves a consortium between 13 partners.

Find here all the documents and tools related to this project.

Stopping Anti-TNF in Crohn’s Disease Remitters: Pros and Cons: The Pros

Stopping Anti-TNF in Crohn’s Disease Remitters: Pros and Cons: The Pros

“Stopping Anti-TNF in Crohn’s Disease Remitters: Pros and Cons: The Pros”, E. LOUIS (Department of Gastroenterology, University and CHU Liège, Liège, Belgium), Inflamm. Intest. Dis. 2022;7:64–68 (DOI: 10.1159/000520942). For more information: BIOCYCLE website: biocycle-project.eu EU reference: grant agreement No 633168 – BIOCYCLE (PHC-13-2014). 10. Stopping Anti-TNF in CD PRO

Presentation JFHOD2022

Presentation JFHOD2022

Arret de l’infliximab ou de l’antimétabolite dans la maladie de Crohn en rémission soutenue sans corticoide sous traitement combiné par infliximab et antimétabolite : essai randomisé controlé de décroissance thérapeutique SPARE », JFHOD2022 – established in the context of Dissemination portfolio 2022 of the BIOCYCLE project. For more information: BIOCYCLE website: biocycle-project.eu EU reference: grant agreement No…